Palmitate-Activated Macrophages Confer Insulin Resistance to Muscle Cells by a Mechanism Involving Protein Kinase C θ and ε by Kewalramani, Girish et al.
Palmitate-Activated Macrophages Confer Insulin
Resistance to Muscle Cells by a Mechanism Involving
Protein Kinase C h and e
Girish Kewalramani
1, Lisbeth Nielsen Fink
1,2, Farzad Asadi
1,3, Amira Klip
1*
1Cell Biology Program, The Hospital for Sick Children, Toronto, Canada, 2Hagedorn Research Institute, Novo Nordisk A/S, Gentofte, Denmark, 3Department of
Biochemistry, School of Veterinary Medicine, University of Tehran, Tehran, Iran
Abstract
Background: Macrophage-derived factors contribute to whole-body insulin resistance, partly by impinging on metabolically
active tissues. As proof of principle for this interaction, conditioned medium from macrophages treated with palmitate (CM-
PA) reduces insulin action and glucose uptake in muscle cells. However, the mechanism whereby CM-PA confers this
negative response onto muscle cells remains unknown.
Methodology/Principal Findings: L6-GLUT4myc myoblasts were exposed for 24 h to palmitate-free conditioned medium
from RAW 264.7 macrophages pre-treated with 0.5 mM palmitate for 6 h. This palmitate-free CM-PA, containing selective
cytokines and chemokines, inhibited myoblast insulin-stimulated insulin receptor substrate 1 (IRS1) tyrosine phosphor-
ylation, AS160 phosphorylation, GLUT4 translocation and glucose uptake. These effects were accompanied by a rise in c-Jun
N-terminal kinase (JNK) activation, degradation of Inhibitor of kBa (IkBa), and elevated expression of proinflammatory
cytokines in myoblasts. Notably, CM-PA caused IRS1 phosphorylation on Ser1101, and phosphorylation of novel PKCh and e.
Co-incubation of myoblasts with CM-PA and the novel and conventional PKC inhibitor Go ¨6983 (but not with the
conventional PKC inhibitor Go ¨6976) prevented PKCh and e activation, JNK phosphorylation, restored IkBa mass and reduced
proinflammatory cytokine production. Go ¨6983 also restored insulin signalling and glucose uptake in myoblasts. Moreover,
co-silencing both novel PKC h and e isoforms in myoblasts by RNA interference, but not their individual silencing, prevented
the inflammatory response and restored insulin sensitivity to CM-PA-treated myoblasts.
Conclusions/Clinical Significance: The results suggest that the block in muscle insulin action caused by CM-PA is mediated
by novel PKCh and PKCe. This study re-establishes the participation of macrophages as a relay in the action of fatty acids on
muscle cells, and further identifies PKCh and PKCe as key elements in the inflammatory and insulin resistance responses of
muscle cells to macrophage products. Furthermore, it portrays these PKC isoforms as potential targets for the treatment of
fatty acid-induced, inflammation-linked insulin resistance.
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Introduction
Low grade inflammation provoked by immune cells contributes
to insulin resistance, a major cause of Type 2 diabetes [1,2]. In
obesity, macrophage infiltration of the expanding adipose tissue
renders adipocytes insulin-resistant, consequently elevating circu-
lating fatty acids and inflammatory cytokines that in turn
contribute to insulin resistance in skeletal muscle [3,4,5,6]. While
the participation of macrophages in triggering adipose tissue
insulin resistance is well established [3,7,8], it is less clear whether
and how macrophage-derived factors affect skeletal muscle.
Recent studies demonstrate the presence of proinflammatory
macrophages infiltrating muscle tissue, whether abutting the
skeletal muscle fibres directly or surrounding muscle-infiltrating
adipocytes in the context of obesity [4,5,6,9]. Cytokines released
by local pro-inflammatory macrophages might directly affect
muscle insulin action. Alternatively or concomitantly, cytokines
produced by pro-inflammatory macrophages in the expanding
adipose tissue may reach muscle in an endocrine fashion (via the
circulation) to render it resistant to insulin. There is growing
evidence that fatty acids trigger macrophages to secrete factors
that impair insulin action [5,10]. In this context, we and others
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26947have shown that fatty acids activate macrophages to release
cytokines that cause insulin resistance in adipocytes and muscle
cells [3,5,10,11]. As proof of concept, we recently reported that
conditioned medium from palmitate-treated macrophages (CM-
PA) provokes insulin resistance in muscle cells at the levels of Akt
signalling, glucose transporter 4 (GLUT4) translocation and
glucose uptake [11], but how CM-PA confers this negative
response onto muscle cells is yet unknown.
In addition to the cytokine-associated insulin resistance, the
most abundant dietary saturated fatty acid palmitate can directly
impair insulin signalling in muscle cells, reducing their insulin-
dependent gain in surface GLUT4 and glucose uptake [12,13,14].
Several mechanisms have been proposed for the generation of
palmitate-induced muscle insulin resistance, in particular the
involvement of diacylglycerol (DAG)-sensitive novel protein kinase
C’s (PKCh, PKCe, PKCd, and PKCg) [15,16,17]. Palmitate and
other fatty acids activate novel PKC’s in skeletal muscle
[16,18,19], thereby curbing downstream insulin signalling
[15,20,21]. PKCh can directly phosphorylate serine residues on
Insulin Receptor Substrate-1 (IRS1) [20], and both PKCh and
PKCe also act upstream of the c-jun N-terminal kinase (JNK) to
inhibit insulin signalling through this inflammatory stress kinase
[22,23,24]. In addition, PKCe can phosphorylate the insulin
receptor to reduce insulin action [25,26]. Notably, PKCh and
PKCe also activate nuclear factor kappa B (NF-kB)-dependent
pathways in muscle cells to promote expression of proinflamma-
tory cytokines and chemokines, major mediators of inflammation-
induced insulin resistance [16,18]. Hence, novel PKC’s intersect
the muscle cell autonomous inflammatory response.
Given that both macrophage-derived factors and saturated fatty
acids cause insulin resistance and activate muscle inflammatory
pathways, and that fatty acids engage novel PKC’s in this response,
we hypothesized that this PKC family may represent a unifying
sensor of dietary and inflammatory signals, that when activated
would interfere with insulin action. Supporting this hypothesis, we
report that CM-PA activates PKCh and e to induce insulin
resistance at the levels of IRS1, Akt Substrate of 160 kDa (AS160),
GLUT4 translocation and glucose uptake, along with the induction
of pro-inflammatory pathways and increased expression of
inflammatory cytokines within muscle cells. The results support
the possibility that, in vivo, the ability of palmitate to induce insulin
resistance may include activating macrophages to secrete proin-
flammatory cytokines and chemokines that would negatively impact
on insulin action in skeletal muscle, acting through novel PKC’s.
Materials and Methods
Materials and Reagents
Antibodies to phospho Akt (Ser473), phospho-AS160, phospho-
JNK (Thr183/Tyr185), phospho-PKCh (Thr538), phospho-IRS1
(Ser1101), phospho-NF-Kappa B (Ser536), NF-Kappa B (p65),
GAPDH and IkBa were from Cell Signaling Technology (Danvers,
MA). Monoclonal (9E10) and polyclonal (A-14) anti-myc antibodies,
monoclonal anti-phosphotyrosine (PY99), antibodies to the insulin
receptor,insulinreceptorsubstrate(IRS)-1,phospho-IRS1(Ser307),
phospho-PKCe (Ser729), anti-histone and polyclonal anti-myc
antibody were from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). PKC inhibitors Go ¨6983 and Go ¨6976 were from Calbiochem
(SanDiego,CA).PredesignedratsiPKCh(59-AACCTCAAGGCC-
GAATGCTAA-39), siPKCe (59-CACGATGAGTTCGTCACT-
GAT-39) and non-related siRNA (siNR) (59-AATAAGGCTAT-
GAAGAGATAC-39) were from Qiagen. Human insulin (Humulin
R) was from Eli Lilly Canada (Toronto, Ontario, Canada).
Cytochalasin B, 2-deoxyglucose (2-DG), protease inhibitor cocktail,
monoclonal antiactinin-1, and other chemicals unless otherwise
noted were from Sigma Chemical (St. Louis, MO). 2-Deoxy-D-
[
3H] glucose was from PerkinElmer (Boston, MA). The RNEasy
Mini kit was from Qiagen (Mississauga, Ontario, Canada).
The SuperScriptH VILO
TM cDNA Synthesis Kit was from
Invitrogen (Burlington, Ontario, Canada). Reagents for quanti-
tative PCR analysis were from Applied Biosystems (Carlsbad, CA).
This includes Fast Advanced master mix and Taqman assays
for detection of Hprt1 (Assay ID: Rn01527840_m1), tumor
necrosis factor a (TNFa, Rn00562055_m1), interleukin 6 (IL6,
Rn01410330_m1), Ptgs2 (COX2, Rn01483828_m1) and Ccl2
(MCP1, Rn00580555_m1) transcripts. The Proteome Profiler
Mouse Cytokine Array Kit, Panel A and recombinant mouse
cytokines/chemokines (CXCL1, CXCL2, CXCL10 and TNFa)
were from RnD Systems (Minneapolis, MN).
L6-GLUT4myc myoblast cell lines and treatments
L6-GLUT4myc myoblasts [27] without or with stable expression
of the Akt substrate AS160 (L6-GLUT4myc-AS160 cells) or of the
insulin receptor (L6-GLUT4myc-IR cells), as indicated, were
cultured in a-MEM supplemented with 10% FBS, blasticidin S
(2 mg/ml), and 1% antibiotic/antimycotic solution (10,000 U/ml
penicillin G, 10 mg/ml streptomycin, and 25 mg/ml amphotericin
B) under 5% CO2 at 37uC. Myoblast cultures were typically
treated with the indicated macrophage conditioned media (CM) or
exogenous cytokines for the times indicated, serum-deprived for
3 h and stimulated with insulin (100 nM, 20 min). Where listed,
Go ¨6983 (1 mM), or Go ¨6976 (1 mM) were used to inhibit PKC’s.
Macrophage treatment with palmitate and collection of
conditioned media (CM)
RAW 264.7 macrophages (purchased from American Type
Culture Collection, Manassas, VA, USA, Catalogue No TIB-71)
were grown in a-MEM supplemented with 1% antibiotic-
antimycotic and 10% fetal bovine serum. A 5 mM palmitate-10%
BSA stock solution was prepared as described [12]. Macrophages
were treated with BSA alone or 500 mM conjugated palmitate/1%
BSA in culture medium for 6 h, then washed several times with
PBS, and fresh medium was added. After 12 h, conditioned media
(CM-BSA, CM-PA) were collected, centrifuged (7 min, 3,500 rpm),
and added to L6-GLUT4myc myoblast cultures for 1 h or 24 h.
Given the intermediate washes, no residual palmitate is expected to
be present in CM-PA. Following the 1 h or 24 h incubation, cells
were washed twice with 0.5 ml PBS and lysed in the appropriate
ice-cold lysis buffer. Cell lysates were used for immunoblotting,
immunoprecipitation and gene expression analysis.
RT-PCR and small interfering RNA (siRNA)-mediated PKC
knockdown
For quantitative PCR (qPCR), RNA was isolated with the
RNEasy Mini kit and used to generate cDNA using The
SuperScriptH VILO
TM cDNA Synthesis Kit (Invitrogen). qPCR
was performed using Fast Advanced master mix (Applied
Biosystems) and Taqman assays for rat TNFa, IL6, monocyte
chemotactic protein 1 (MCP-1) and cyclooxygenase 2 (COX-2)
according to the manufacturer’s instructions. The input of cDNA
was 10 ng/reaction. qRT-PCR was performed at 50uC/2 min,
95uC/20 sec followed by 40 cycles of 95uC/1 sec and 60uC/
20 sec. Comparative cycle threshold results expressed relative to
hprt1 were used. For PKCh and PKCe knockdown, L6GLUT4-
myc myoblasts were treated with 100 nM siRNA to PKCh
(PKCh siRNA) (AACCTCAAGGCCGAATGCTAA) or siRNA
to PKCe (PKCe siRNA) (CACGATGAGTTCGTCACTGAT) or
Novel PKC’s in Muscle Insulin Resistance
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max reagent (Invitrogen).
Immunoblotting and immunoprecipitation
Confluent L6-GLUT4myc myoblasts in 10 cm diameter dishes
were treated as indicated and immediately processed for SDS-
PAGE and immunoblotting as described [28]. IRS1 in cell lysates
was immunoprecipitated using an anti-IRS1 antibody. The
immunocomplex and the supernatant were resuspended in
Laemmli buffer and heated for 5 min at 95uC. The immunocom-
plex was separated into two equal portions, separated by SDS-
PAGE and immunoblotted with anti-phosphotyrosine, antipho-
spho-IRS1(Ser307)orantiphospho-IRS1(Ser1101),andanti-IRS1.
Nuclear localization of Nuclear Factor-Kappa B (NF-kappa B)
A nuclear extract kit (Active Motif, CA) was used to obtain
cytosolic and nuclear fractions from L6 myoblasts. Briefly, after
treatments, cellswerescraped and centrifuged for5 min at 500 rpm
at 4uC. resuspended in hypotonic 16 buffer and detergent-
extracted. The suspension was centrifuged for 30 s at 14,000 g at
4uC, yielding the cytoplasmic fraction in the supernatant and a
nuclear pellet that was re-purified. Samples were analyzed for
phosphorylated or total NF-Kappa B/p65 (1:1000).
2-deoxy-[3H]glucose uptake and cell surface GLUT4myc
L6-GLUT4myc myoblasts grown in 24-well plates and serum-
deprived for 3–5 h, then treated with or without insulin (100 nM,
20 min). 2-Deoxyglucose uptake was measured as described [28],
and cell surface GLUT4myc was measured as described [27,29].
Cytokine and chemokine determination and treatment
CM-PA & CM-BSA were analyzed for multiple cytokines and
chemokines by Proteome Profiler Mouse Cytokine Array (RnD
Systems) according to the manufacturer’s instructions for cell
culture supernatants. Membranes were exposed to autoradiogra-
phy film for 1 s, 30 s or 2 min. Protein spots were quantified using
ImageJ software (NIH, USA). To examine the impact of cytokines
and chemokines on activation of PKCh and e, myoblasts were
incubated with cytokines and chemokines (0–100 ng/ml) individ-
ually or in combination, for 24 h. Subsequently cells were washed
and lysed in the appropriate ice-cold lysis buffer prior to
immunoblotting.
Measurement of non-esterified fatty acids (NEFAs) in
media
NEFA levels were measured according to the ACS.ACOD (Acyl
CoA synthase - Acyl CoA oxidase) method using the HR series
NEFA-HR kit No. 999-34691 (Wako Pure Chemical Industries,
Osaka, Japan).
Statistical analysis
Values are means 6 SE. Wherever appropriate, one-way
ANOVA followed by Tukey or Bonferroni tests was used to
determine differences between group mean values. The level of
statistical significance was set at P,0.05.
Results
CM-PA increases IRS1 serine phosphorylation and
reduces its tyrosine phosphorylation in response to
insulin
We have previously reported a drop in insulin-stimulated
phosphorylation of Akt on Ser473 in L6 myoblasts treated with
ceramides as a model of lipotoxicity [30] or with conditioned
medium from palmitate-treated macrophages (CM-PA) as a model
of inflammatory toxicity [11]. The ceramide effect was not
accompanied by upstream signalling defects at the level of IRS1,
the substrate of the insulin receptor relevant for GLUT4 traffic
[31]. However, a defect at this first step in insulin action is often
observed in conditions of in vivo insulin resistance. Hence we first
assessed whether macrophage-conditioned media alters insulin
signalling at the level of IRS1. In myoblasts incubated with
medium from untreated macrophages (regular medium, RM) or
CM-BSA, insulin increased tyrosine phosphorylation of IRS1 by
approximately 2 fold (Fig. 1A). On the other hand, in myoblasts
treated with CM-PA, insulin-stimulated tyrosine phosphorylation
of IRS1 was significantly reduced (4566%, Fig. 1A). No change in
IRS1 tyrosine phosphorylation was observed in the absence of
insulin. Phosphorylation of IRS1 on selective serine residues can
reduce its tyrosine phosphorylation in response to insulin [32].
Indeed, when compared with CM-BSA, CM-PA significantly
increased myoblast IRS1 phosphorylation at serine 307 and 1101
(1.760.2-fold vs CM-BSA and 1.660.1-fold vs CM-BSA, Fig. 1B
and 1C).
CM-PA activates novel PKCh and PKCe in L6 myoblasts
Pro-inflammatory cytokines and chemokines activate PKCh
and e [33,34], and these kinases can lead to IRS1 serine
phosphorylation thereby reducing its tyrosine phosphorylation
and downstream activation of Akt [15,20,21]. Since we have
observed elevated levels of the cytokine TNFa in CM-PA [11], we
next explored whether CM-PA activates novel PKC’s in
myoblasts. PKCh is activated by phosphorylation of Thr538 in
its activation loop, and PKCe through phosphorylation of Ser729
within its carboxyl-terminal hydrophobic site [35,36,37,38]. We
found that while incubating myoblasts for 24 h with RM or CM-
BSA had no effect on either PKC phosphorylation, CM-PA
caused an approximate 1.6-fold rise in each PKCh Thr538 and
PKCe Ser729 phosphorylation, without changing either PKC
protein content (Fig. 2A and 2B). Of note, incubating myoblasts
with CM-BSA or CM-PA for an acute period of 1 h had no effect
on either PKC phosphorylation (Fig. S1). To verify if the CM-PA-
induced PKCh and PKCe activation influenced insulin signalling,
we first used the novel and conventional PKC inhibitor Go ¨6983
and the conventional PKC inhibitor Go ¨6976. Go ¨6983 or Go ¨6976
had no effect on myoblast PKCh or PKCe phosphorylation in
unchallenged cells (data not shown). In the presence of CM-PA,
Go ¨6983 abrogated the increase in PKCh and PKCe phosphor-
ylation (Fig. 2C and Fig. 2D). As expected, Go ¨6976 did not alter
the CM-PA-induced PKCh or PKCe activation (Fig. 2E and 2F).
Inhibition of novel PKC’s prevents the reduction in
insulin-dependent IRS1 tyrosine phosphorylation
provoked by CM-PA
Phosphorylation of IRS1 at a number of susceptible serine
residues lowers insulin signalling by reducing its insulin-stimulated
tyrosine phosphorylation. In particular, PKCh can directly induce
phosphorylation of IRS1 at serine 1101 in muscle [20]. There is
no known, direct PKCe-dependent IRS1 phosphorylation al-
though both PKCh and PKCe can affect IRS1 acting through
JNK [22,23,24], and PKCe can modulate insulin receptor
function and attenuate downstream insulin signalling [25,26].
Given that CM-PA activated both PKC’s, we investigated whether
the deleterious actions of CM-PA on IRS1 were averted by the
novel and conventional PKC inhibitor Go ¨6983. Indeed, Go ¨6983
abrogated the CM-PA-induced increase in phosphorylation of
Novel PKC’s in Muscle Insulin Resistance
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(Fig. 3A). In contrast, although CM-PA reduced the insulin
dependent tyrosine phosphorylation of the insulin receptor, this
response was not restored by Go ¨6983 (Fig. S2). We previously
documented an increase in c-jun N-terminal kinase (JNK)
phosphorylation in myoblasts treated with CM-PA [11]. As both
PKCh and PKCe can also act via JNK to increase IRS1
phosphorylation at Ser307 [22,23,24], we assessed whether novel
PKC inhibition prevented CM-PA-induced JNK and IRS1
Ser307 phosphorylation. Indeed, myoblast treatment with
Go ¨6983 markedly reduced both these effects of CM-PA, without
changing the total JNK or IRS1 content (Fig. 3B and 3C).
Importantly, the Go ¨6983-induced loss of IRS1 serine phosphor-
ylation was accompanied by restoration of insulin induced IRS1
tyrosine phosphorylation (Fig. 3D). Of note, the conventional
PKC inhibitor Go ¨6976 failed to restore the CM-PA-mediated
drop in IRS1 tyrosine phosphorylation (data not shown). These
results suggest that the effects on IRS1 caused by CM-PA are
mediated through its activation of PKCh and PKCe.
Go ¨6983 reverses the drop in insulin-stimulated Akt and
AS160 phosphorylation evoked by CM-PA
Downstream of IRS1, phosphoinositide 3-kinase (PI3K) acti-
vates Akt that in turn phosphorylates the RAB-GAP AS160, to
allow activation of Rabs 8A and 13 that are essential for GLUT4
translocation in muscle cells [39]. Exposing myoblasts to CM-PA
for 24 h reduced insulin-stimulated phosphorylation of Akt on
Ser473 (Fig. 4A) and importantly caused a more robust drop in
AS160 phosphorylation, signifying severe impairment in down-
stream insulin signalling (Fig. 4B). Consistent with the lack of
stimulation of PKCs, comparable levels of insulin-stimulated Akt
and AS160 phosphorylation were observed in myoblasts incubated
with CM-PA for an acute period of 1 h (Fig. S3), suggesting that a
long-term incubation is required for CM-PA to induce impairment
in insulin signalling. Given that Go ¨6983 prevented the long-term,
deleterious effects of CM-PA on IRS1, we explored whether
downstream signalling was similarly restored. Indeed, this novel
and conventional PKC inhibitor abolished the negative impact of
CM-PA and restored insulin-stimulated Akt (Fig. 4A) and AS160
phosphorylation (Fig. 4B) without affecting basal state phosphor-
ylation. In contrast, the conventional PKC inhibitor Go ¨6976 did
not prevent either effect of CM-PA (data not shown).
Novel PKC inhibition prevents the reduction of
GLUT4myc translocation and glucose uptake caused by
CM-PA
Insulin action through IRS1, Akt and AS160 stimulates glucose
uptake by increasing GLUT4 glucose transporters at the plasma
Figure 1. CM-PA impairs insulin stimulated tyrosine phosphorylation of IRS-1 in L6-GLUT4myc myoblasts. L6-GLUT4myc myoblasts
were incubated for 24 h with RM, CM-BSA or CM-PA from RAW macrophages. Cells were lysed, immunoprecipitated using IRS-1 antibody and
subjected to SDS-PAGE either directly or following stimulation with insulin (100 nM for 10 min). A; Representative immunoblots and densitometric
quantification for tyrosine phosphorylated IRS-1 (pY) relative to total IRS-1.Bas, Basal; Ins, Insulin treated; p, phosphorylated. Results are mean 6 SE of
3 separate experiments. *Significantly different from basal,
#Significantly different from CM-BSA insulin, P,0.05. B; Representative immunoblots and
densitometric quantification for IRS-1 phosphorylation at Ser307 and C; Ser1101 relative to total IRS-1. Results are mean 6 SE of 3 separate
experiments. *Significantly different from CM-BSA, P,0.05.
doi:10.1371/journal.pone.0026947.g001
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PA, insulin-stimulated gain in surface GLUT4myc translocation
(Fig. 5A) and glucose uptake (Fig. 5B) were significantly reduced
when compared with CM-BSA, confirming our previous obser-
vations [11]. Notably, the novel PKC inhibitor Go ¨6983 prevented
the CM-PA- induced insulin resistance of GLUT4myc transloca-
tion and its consequent glucose uptake, such that the decreases in
either parameter below the insulin-stimulated CM-BSA were no
longer statistically significant (Fig. 5A and B). In contrast, Go ¨6976
did not restore insulin action on these metabolic outcomes (Fig. 5A
and B).
Specific cytokines and chemokines in macrophage-
conditioned media fail to activate novel PKC’s in muscle
cells
Several studies have shown that macrophage-derived cytokines
and chemokines such as TNFa and MCP-1 can directly elicit
adipose cell inflammation and insulin resistance [40,41]. Accor-
dingly, it is likely that secreted cytokines in the conditioned
media from palmitate-treated macrophages propagate inflam-
matory stress response and insulin resistance in muscle cells. Our
previous studies showed elevated levels of TNFa in CM-PA
compared to CM-BSA [11]. A more detailed analysis of this
conditioned media in the present study validated that observation
and further demonstrated markedly elevated levels of MCP-1
(CCL2), MIP2 (CXCL2), IP10 (CXCL10), KC (CXCL1) and
CCL7 (Fig. 6A). Besides macrophage-derived factors, residual
palmitate or fatty acids potentially released by the macrophages
might also be present in CM-PA, even though palmitate was
removed after 6 h, macrophages washed several times with PBS
and fresh medium added for 12 h to collect conditioned media.
To investigate these possibilities, we measured the levels of non-
esterified free fatty acids (NEFA) in CM-PA. Fig. 6A (inset) shows
that there was no difference in NEFA’s in CM-PA compared to
CM-BSA, and moreover the levels detected fall below those
reported in the literature to affect insulin action in muscle [12].
This result suggests that a protein component is likely involved in
the observed defect in myoblast insulin signalling. To examine
the individual impact of small protein molecules like cytokines
and chemokines on activation of PKC theta and epsilon,
myoblasts were incubated individually for 24 h with different
concentrations (0–100 ng/ml) of the most differentially elevated
cytokines and chemokines found in CM-PA compared to
Figure 2. CM-PA causes activation of novel PKCh and PKCe in L6-GLUT4myc myoblasts. L6-GLUT4myc myoblasts were treated for 24 h
with RM, CM-BSA and CM-PA. Where indicated, cells were pre-incubated for 30 min with the novel and conventional PKC inhibitor, Go ¨6983 (1 mM) or
the conventional PKC inhibitor, Go ¨6976 (1 mM), prior to addition of CM-PA. After 24 h, cells were lysed, and equal amount of total protein from each
sample were immunoblotted with specific antibodies against phospho-Thr538 PKCh, total PKCh (A, C and E), phospho-Ser729 PKCe, total PKCe or
GAPDH (B, D and F). Representative immunoblots and densitometric quantification of three experiments are shown. Values are expressed as ratio of
phosphorylated protein relative to GAPDH or total levels of respective protein. Results are mean 6 SE. *Significantly different from CM-BSA, P,0.05.
#Significantly different from CM-PA, P,0.05.
doi:10.1371/journal.pone.0026947.g002
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on PKCh or PKCe phosphorylation was observed in muscle cells
challenged individually with these cytokines or chemokines at
indicated concentrations (Fig. 6B). We further tested the effect
these cytokines and chemokines combined, using the following
concentrations: TNFa (1 ng/ml), MIP2 (2 ng/ml), IP10
(1 ng/ml) and KC (10 ng/ml). However, like the individual
cyto/chemokine treatments, the combination treatment also
failed to elicit any rise in PKCh and PKCe phosphorylation
(Fig. 6B).
Figure 3. Novel PKC inhibition prevents the JNK activation and drop in insulin-stimulated tyrosine phosphorylation of IRS1 caused
by CM-PA. L6-GLUT4myc myoblasts were treated for 24 h with RM, CM-BSA and CM-PA. Where indicated, cells were pre-incubated for 30 mins with
the novel and conventional PKC inhibitor, Go ¨6983 (1 mM), prior to addition of CM-PA. Cells were lysed, immunoprecipitated using IRS-1 antibody and
subjected to SDS-PAGE either directly or following stimulation with insulin (100 nM for 10 min). Representative immunoblots and quantification of
phosphorylation of Ser1101-IRS1 (A), Ser307-IRS1 (C) and tyrosine residues (D). For direct immunoblotting, cells were lysed, and equal amount of
total protein from each sample were immunoblotted with specific antibodies against phospho-JNK and total JNK (B). Representative immunoblots
and quantification of three to four experiments are shown. Values are expressed as ratio of phosphorylated protein relative to total levels of
respective protein. Results are mean 6 SE *Significantly different from basal or CM-BSA, P,0.05,
#Significantly different from CM-BSA insulin or CM-
PA, P,0.05.
doi:10.1371/journal.pone.0026947.g003
Novel PKC’s in Muscle Insulin Resistance
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26947Macrophage-conditioned media causes IKBa
degradation, promotes NF-kappa B nuclear translocation
and elevates the expression of pro-inflammatory
cytokines
Muscle can mount an autonomous inflammatory stress response
to cytokines and chemokines, evinced by degradation of IKBa and
the consequent activation of NF-kB dependent gene transcription
through post-translational modifications of the NF-kB p65 subunit
[42,43,44,45]. Consistent with this behaviour, we previously
reported that CM-PA promotes IKBa degradation and elevates
the expression of proinflammatory cytokines in the target myoblasts
[11]. As PKCh and PKCe have been demonstrated to act upstream
of IKBa [46,47], we here hypothesized that inhibition of novel
PKC’s would prevent the CM-PA-driven IKBa degradation and
subsequent responses. This was found to be the case, as Go ¨6983
prevented IKBa degradation by 8169% (Fig. 7A) in myoblasts
incubated with CM-PA for 24 h, and further significantly reduced
the CM-PA dependent augmentation in MCP-1 and TNFa gene
expression (Fig. 7C). Interestingly, there was no significant change
in myoblast IL-6 or COX-2 gene expression in myoblasts treated
with CM-PA (Fig. 7C), indicating that the effects of CM-PA are
selective rather than the result of a generalized inflammatory
response by the muscle cells. To directly confirm the activation of
NF-kB, the phosphorylation status of its main p65 phosphorylation
site, Ser536, was examined. Incubation of myoblasts with CM-PA
forupto24 h increasedthecytosolicphosphorylationofNF-kB p65
at Ser536 starting at 18 h and peaking at 24 h (Fig. 7B). Further,
nuclear translocation is crucial for NF-kB to exert its transcriptional
effects. We found that 24 h of CM-PA treatment stimulated NF-kB
nuclear translocation (Fig. 7B).
Co-silencing PKCh and PKCe expression prevents the
inhibition of insulin signalling caused by CM-PA
The results described so far revealed that palmitate-treated
macrophages produce a selective array of cytokines and chemokines
into a complex CM-PA, which in turn unleashes insulin resistance
and inflammatory responses within muscle cells. These responses
were largely ascribed to novel PKC activation, based on the
alleviation of these deleterious effects by Go ¨6983 but not Go ¨6976.
To specifically ascertain that CM-PA indeed acted through PKCh
and PKCe in its ability to alter insulin action, we aimed to silence
PKCh and PKCe expression in myoblasts via siRNA. We first
validated successful PKCh and PKCe knockdown by immunoblot-
ting (Fig. 8A). Knockdown of either PKCh or PKCe alone by their
corresponding siRNA did not prevent the reduction in insulin-
stimulated phosphorylation of Akt or AS160 induced by CM-PA
(Fig. S4 A & B). Interestingly, however, knockdown of PKCh alone
enhanced by 3164% the activating phosphorylation of PKCe
observed with CM-PA (Fig. 8B). As this suggested a redundant or
perhaps cooperative action of these proteins in their ability to
interfere with insulin action, we enquired whether silencing both
proteins together could overcome the deleterious effects of CM-PA
on muscle cells. Myoblasts were transfected with a mix of siRNAs to
both PKCh and PKCe prior to challenging them with CM-PA.
Figure 4. Novel PKC inhibition prevents the decrease in insulin-stimulated phosphorylation of Akt and AS160 caused by CM-PA. L6-
GLUT4myc myoblasts with or without stable expression of AS160 (L6-GLUT4myc-AS160) were incubated as described in Fig. 3, and then stimulated in
the presence or absence of insulin (100 nM, 10 min). Cells were lysed, and equal amount of total protein from each sample were immunoblotted with
specific antibodies against phospho-Akt (Ser473) and total Akt (A), or phospho-AS160 and total AS160 (B). Representative immunoblots and
quantification of three experiments are shown. Values are expressed as ratio of phosphorylated protein relative to total levels of the respective
protein. Results are the means 6 SE *Significantly different from basal, P,0.05,
#Significantly different from CM-BSA insulin, P,0.05.
doi:10.1371/journal.pone.0026947.g004
Novel PKC’s in Muscle Insulin Resistance
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(Fig. 8C) and PKCe content by 7663% (Fig. 8C) in this manner
virtually abolished the inhibition in insulin-stimulated phosphory-
lation of Akt (Fig. 8D) and AS160 (Fig. 8E) provoked by CM-PA.
Co-silencing PKCh and PKCe expression prevents the
effect of CM-PA on myoblast GLUT4myc translocation
and glucose uptake
We finally sought to ascertain that the metabolic consequence of
the macrophage-derived media on muscle cells was specifically
mediated by PKCh and PKCe. Indeed, co-silencing both PKC
isoforms relieved insulin resistance, by preventing the drop in
insulin stimulated GLUT4myc translocation (Fig. 9A) and glucose
uptake (Fig. 9B) caused by CM-PA.
Discussion
Resident macrophages are an essential component of skeletal
muscle. Positive functions of macrophages include contribution to
regeneration and revascularization when in their M2 (anti-
inflammatory) phenotypic polarization [1]. However, macrophag-
es can also become M1 polarized (inflammatory), which results in
inflammatory cytokine production [1]. In cell culture, products
from inflammatory macrophages can confer insulin resistance to
muscle cells, as in the case of fatty acid-treated RAW macrophages
and L6 myoblasts [1,5,11]. However, the signalling mechanism by
which macrophage-derived factors confer this negative response
onto muscle cells is poorly understood. The present study shows
that conditioned media from palmitate-treated macrophages (CM-
PA) activates novel PKCh and PKCe that appear to be responsible
for induction of pro-inflammatory gene expression, cytokine
production and metabolic insulin resistance in muscle cells. Since
only very low levels of NEFA’s were detected in the conditioned
media and these levels did not differ between CM-PA and CM-
BSA, it is unlikely that any residual fatty acid is responsible for the
activation of these kinases in the muscle cells.
An interplay between fatty acids and macrophages to promote
muscle cell insulin resistance is now recognized. Previous studies
Figure 5. Novel PKC inhibition blunts the deleterious effect of CM-PA on insulin-stimulated GLUT4 exocytosis and glucose uptake.
L6-GLUT4myc myoblasts were treated for 24 h with RM, CM-BSA, CM-PA, or CM-PA supplemented with Go ¨6983 (1 mM). Following 2 h of serum
starvation, myoblasts were stimulated in the presence or absence of insulin (100 nM for 20 min) and then assayed for cell surface density of
GLUT4myc (A) or 2-DG uptake (B). Data are presented as the means 6 SE of 3 experiments. *Significantly different from basal, P,0.05,
#Significantly
different from CM-BSA insulin, P,0.05.
doi:10.1371/journal.pone.0026947.g005
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26947Figure 6. Specific cytokines/chemokines identified in conditioned media fail to activate novel PKC’s in muscle cells. A, Palmitate
treatment induces differential secretion of cytokines and chemokines by macrophages, revealed through a Proteome Profiler Mouse Cytokine Array.
Values are expressed as the ratio of expression in CM-PA over CM-BSA, and represent the means 6 SE of 2 separate experiments. NEFA levels were
measured using HR series NEFA-HR kit No. 999-34691 (inset). Values are presented as the means 6 SE of 3 experiments. B, L6-GLUT4myc myoblasts
were incubated individually or in combination with different concentrations (0–100 ng/ml) of TNFa, MIP2, IP10 or KC for 24 h. Cells were lysed, and
equal amount of protein from each sample were immunoblotted with specific antibodies against phospho-PKCh (Thr538) and phospho-PKCe
(Ser729). Representative immunoblots of three experiments are shown.
doi:10.1371/journal.pone.0026947.g006
Novel PKC’s in Muscle Insulin Resistance
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e26947Figure 7. CM-PA promotes IkBa degradation, NF-kappa B nuclear translocation and induces the expression of cytokines and
chemokines in myoblasts. A, Representative immunoblots and densitometric quantification of IkBa and actinin-1 after exposure of L6-GLUT4myc
myoblasts to RM, CM-BSA, CM-PA, or CM-PA supplemented with Go ¨6983 (1 mM). Actinin-1 served as internal loading control, and values are
expressed as IkBa to actinin-1 ratio. Results are the mean 6 SE of three independent experiments. B, L6-GLUT4myc myoblasts were treated for 18 or
24 h with RM, CM-BSA and CM-PA, and cytoplasmic and nuclear fractions were obtained. Cells were lysed, and equal amount of protein from each
sample were immunoblotted with specific antibodies against phosphorylated NF-kappa B (pSer536) and total NF-kappa B/p65. Histone and total NF-
kappa B were used as controls. Representative immunoblots and quantification of three experiments are shown. C, Representative densitometric
quantification of transcript levels of MCP-1, TNFa, IL-6 and COX-2. Results are the mean 6 SE of three independent experiments. *Significantly
different from all other groups, P,0.05.
doi:10.1371/journal.pone.0026947.g007
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bone marrow-derived macrophages reduces glucose uptake in
muscle cells [5]. Building on those observations, we have shown
that the saturated fatty acid palmitate polarizes macrophages of
the RAW264.7 cell line towards the inflammatory M1 phenotype.
Moreover, CM-PA from such macrophages renders L6 muscle
cells insulin-resistant [11]. In the present study, an analysis of CM-
PA revealed markedly elevated levels of selective cytokines and
chemokines such as TNFa, MCP-1, MIP2, IP10, and KC.
Notably, TNFa, MCP-1, IP10, and KC have been shown to
activate PKC’s and induce inflammatory stress via NF-kB
[33,45,48,49,50]. Interestingly, we found no effect on PKCh or
PKCe phosphorylation in muscle cells challenged with these
cytokines or chemokines, individually or in combination, suggest-
ing that other macrophage-released products or their combina-
tions are responsible for the biological effects of CM-PA. Future
analysis will make it possible to dissect out whether and which
other chemokines/cytokines are responsible for the insulin
resistance and the inflammatory responses conferred to muscle
cells.
Novel PKC’s reduce insulin signalling at the level of IRS1
PKC activation is one of several pathways leading to Ser/Thr
phosphorylation of IRS proteins, mainly IRS1 [51]. Serine
phosphorylation of IRS1 at a number of susceptible sites
attenuates downstream insulin signalling by reducing its insulin-
stimulated tyrosine phosphorylation. Studies suggest that phos-
phorylation of mouse IRS1 at Ser307 (Ser312 in human IRS1) is
important for inflammatory stimuli-mediated inhibition of IRS1
function [20]. Here we document an increase in IRS1 Ser307
phosphorylation in muscle cells exposed to CM-PA. Activation of
novel PKC’s may not mediate Ser307 phosphorylation directly,
since this site is not recognized as a direct target of these kinases,
yet inhibiting novel PKC’s prevented this phosphorylation. This
Figure 8. Novel PKC silencing reverses CM-PA mediated drop in insulin-stimulated phosphorylation of Akt and AS160. L6-GLUT4myc
myoblasts were incubated with non-related siRNA (NR), siRNA to PKCh (PKCh siRNA), siRNA to PKCe (PKCe siRNA) or a combination of both (PKCh+e)
using lipofectamine RNAi-max reagent. A and C, knockdown efficiency PKCh and PKCe, respectively. B, L6-GLUT4myc myoblasts were treated for 24 h
with RM, CM-BSA, CM-PA or CM-PA supplemented with siRNA to PKCh (PKCh siRNA). After 24 h, cells were lysed and each sample was
immunoblotted with specific antibodies against phospho-PKCe (Ser729) and total-PKCe. Results are the means 6 SE of three separate experiments
*Significantly different from CM-BSA, P,0.05,
#Significantly different from CM-PA, P,0.05. D and E, L6-GLUT4myc myoblasts with or without stable
expression of AS160 (L6-GLUT4myc-AS160) were treated for 24 h with RM, CM-BSA, CM-PA or CM-PA supplemented with siRNA to both PKCh and
PKCe. Following 24 h treatment, cells were stimulated in the presence or absence of insulin (100 nM, 10 min). Cells were lysed, and equal amount of
total protein from each sample were immunoblotted with specific antibodies against phospho-Akt (Ser473), total Akt, phospho-AS160 and total AS-
160. Results are mean 6 SE of three separate experiments *Significantly different from basal, P,0.05,
#Significantly different from CM-BSA insulin,
P,0.05.
doi:10.1371/journal.pone.0026947.g008
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upstream of JNK [22,23,24], the kinase directly responsible for
Ser307 phosphorylation [52]. In addition, CM-PA caused IRS1
phosphorylation at Ser1101, a site that can be directly phosphor-
ylated by novel PKCh in muscle cells and tissue [20]. Because
Ser1101 phosphorylation has been consequently linked to reduced
IRS-1 tyrosine phosphorylation and downstream insulin signalling
[20], we hypothesized that PKCh may be directly responsible for
the reduction in IRS1 signalling in muscle cells challenged with
CM-PA. Indeed, we report that chemical inhibition of novel PKC’s
or silencing gene expression of PKCh and PKCe prevents both
IRS1 Ser1101 phosphorylation and tyrosine phosphorylation.
Besides IRS1, CM-PA treatment of myoblasts reduced the
insulin-dependent tyrosine phosphorylation of the insulin receptor.
More than one mechanism may be responsible for this effect. Pro-
inflammatory cytokine administration to muscle cells increases the
activity of protein-tyrosine phosphatase 1B (PTP1B) that dephos-
phorylates phosphotyrosine residues in the insulin receptor [53]. It
is therefore possible that inflammatory factors present in CM-PA
contribute to the observed reduction in insulin receptor tyrosine
phosphorylation via phosphatase like PTP1B. Serine phosphory-
lation of IRS1, via a feedback loop, might also inhibit insulin
receptor tyrosine kinase activity [54], which may explain the
decrease in insulin receptor tyrosine phosphorylation observed
with CM-PA (however, this would not be mediated by IRS1
phosphorylation on Ser307 or Ser1101, see below).
CM-PA acts through novel PKC’s to reduce Akt and
AS160 responses to insulin
Down-stream of IRS1, activation of Akt by insulin requires
hierarchical phosphorylation on two residues, Thr308 and Ser473
[55]. CM-PA treatment of myoblasts resulted in a small reduction
in insulin-stimulated phosphorylation of Akt at Ser473. It is
possible that this mild reduction in Akt may not suffice per se to
impose GLUT4 resistance downstream, since studies show that
much greater reductions are required for this metabolic outcome
[55,56,57]. However, the more marked inhibition of AS160
phosphorylation observed with CM-PA reveals an amplification of
Figure 9. Co-silencing novel PKCh and PKCe prevented the deleterious effect of CM-PA on insulin-stimulated GLUT4 translocation
and glucose uptake. L6-GLUT4myc myoblasts were treated for 24 h with RM, CM-BSA, CM-PA, or CM-PA supplemented with siRNA to both PKCh
and PKCe (100 nM each). Following 2 h of serum starvation, myoblasts were stimulated in the presence or absence of insulin (100 nM for 20 min) and
then assayed for cell surface density of GLUT4myc (A) or 2-deoxyglucose uptake (B). Data are presented as means 6 SE of 3 experiments.
*Significantly different from basal, P,0.05,
#Significantly different from CM-BSA insulin, P,0.05.
doi:10.1371/journal.pone.0026947.g009
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insulin-stimulated GLUT4 translocation and glucose uptake. Like
novel PKC’s, activation of conventional PKC isoforms (a, bI, bII,
and c) is associated with inhibition of early steps in the insulin
signalling cascade [58,59]. As Go ¨6983 (novel and conventional
PKC inhibitor) but not Go ¨6976 (specific conventional PKC
inhibitor), restored insulin signalling through the IRS1, Akt and
AS160 leading to normalization of muscle glucose uptake, our
findings suggest that the CM-PA-induced block in insulin action
downstream of the insulin receptor is mediated by novel PKC’s,
likely PKCh and e. Failure of Go ¨6983 to prevent the drop in
insulin receptor tyrosine phosphorylation advocates that the effect
of CM-PA on the insulin receptor is mediated by a mechanism not
involving novel PKC’s. Further, since Go ¨6983 restored the
impairment of downstream insulin signalling in attendance of
reduced insulin receptor tyrosine phosphorylation, it can be
concluded that the partial alteration in insulin receptor function
has no consequence on downstream insulin action.
CM-PA elicits inflammatory responses in muscle cells
mediated by novel PKC’s
Activation of the NF-kB signalling cascade is pivotal to
inflammatory responses and insulin resistance in muscle cells
[60]. In the resting state, IkBa proteins restrict the NF-kB dimer in
the cytoplasm. Phosphorylation of IkBa by IkB kinase induces its
proteasomal degradation, releasing the NF-kB heterodimer to
translocate to the nucleus and regulate proinflammatory gene
expression [60]. Interestingly, we found that Go ¨6983 prevented
the IkBa degradation and induction of inflammatory cytokine/
chemokine (TNFa and MCP1) gene expression in muscle cells
caused by CM-PA. Hence we propose that the inflammatory
response of muscle cells challenged by CM-PA is mediated
through novel PKC’s. These results add to a growing number of
studies showing involvement of novel PKC’s in cell autonomous
inflammation: In pancreatic acinar cells, TNFa activates novel
PKCd and e to regulate NF-kB mediated gene transcription [33].
In the human eosinophilic leukemia cell line EoL-1, MCP-1
activates PKCd to promote an NF-kB mediated inflammatory
response [45]. Direct treatment of C2C12 muscle cells with
palmitate elevates IL-6 gene expression via activation of NF-kB
and PKC and concomitantly reduces insulin signalling [61].
Palmitate also activates NF-kB and promotes pro-inflammatory
cytokine expression by a mechanism involving novel PKC’s in
C2C12 and L6 skeletal muscle cells [16,18]. Hence, fatty acids and
cytokines alike, such as those present in CM-PA, activate novel
PKC’s in muscle cells to in turn cause insulin resistance.
Identification of PKCh and PKCe as the mediators of CM-
PA-induced inflammation and insulin resistance in
muscle cells
A major goal of this study was to identify the PKC isoforms
responsible for CM-PA- induced insulin resistance. Because
Figure 10. Proposed mechanisms involved in the effects of macrophage-derived factors on muscle cells. Cytokines in macrophage-
conditioned medium (CM-PA) impinge on muscle cells to activate novel PKCh and PKCe. Activation of these novel PKC isoforms may be a
consequence of diacylglycerol (DAG) formation in response to pro-inflammatory factors present in CM-PA. PKCh and e activation stimulated Ser1101
phosphorylation on IRS-1 directly and Ser307 on IRS-1 via PKC-mediated JNK activation. Serine phosphorylated of IRS-1 reduced phosphotyrosine and
this is associated with reduced insulin signaling to Akt and AS160 and GLUT4 exocytosis to the plasma membrane and glucose uptake. PKC activation
also mediates NF-kappa B activation (via IkBa degradation) and pro-inflammatory gene expression (e.g. TNFa and MCP-1). The release of these factors
may act in autocrine and paracrine modes to further impair insulin-stimulated glucose uptake.
doi:10.1371/journal.pone.0026947.g010
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available for most PKC’s, the most convincing way to demonstrate
a causative role for a particular isoform in the generation of insulin
resistance is to compare effects in cells transfected with isoform-
specific siRNA sequences. Co-silencing both PKCh and e by RNA
interference (but not individual PKC silencing) prevented the
inflammatory response and restored insulin sensitivity to CM-PA-
treated muscle cells. These results suggest that among novel
PKC’s, the PKCh and e isoforms may be critical for CM-PA-
induced inflammation and insulin resistance. Further, single
knockdown of PKCh is compensated by increased activation of
PKCe in CM-PA treated myoblasts, suggesting that an additional
role for PKCe in muscle cells is unmasked.
PKCh and PKCe involvement in insulin resistance in vivo
PKCh and PKCe have emerged as strong candidates for
mediating lipid-induced insulin resistance. In mice, PKCh inacti-
vation prevents lipid infusion-induced defects in insulin signalling
and glucose transport in skeletal muscle [62]. In addition, knockout
of each PKCh or PKCe genes in mice enhances insulin signalling
and glucose tolerance, and protect against fat induced insulin
resistance [62,63]. This collective evidence points to a pivotal role
for these novel PKC’s in insulin resistance in vivo. Our results add a
new dimension to this connection, by suggesting the possibility that,
in the context of high fat diets or fatty acid infusion, cytokines are
released by pro-inflammatory macrophages (activated by adipose
tissue-derived or circulating fatty acids), which in turn impinge on
muscle, to activate PKCh and PKCe in muscle cells. We speculate
that activation of these novel PKC isoforms may be a consequence
of diacylglycerol formation in response to pro-inflammatory factors
present in CM-PA, since there is precedent that cytokine treatment
promotes diacylglycerol formation in muscle cells [34]. Finally, our
findingsrevealthatsilencingeitherPKCisoformalonewouldnotbe
a suitable pharmacological strategy to overcome inflammation and
insulin resistance in the context of high fat diets, and instead suggest
that combined inhibition of both PKCh and e would be far more
beneficial.
Insummary,wereportthatthattheblockinmuscleinsulinaction
brought about by CM-PA is mediated by the novel PKCh and
PKCe. Both isoforms, directly and/or via the stress kinase JNK
inhibit insulin signalling at the level of IRS1, Akt and AS160
lowering insulin-dependent GLUT4 translocation and glucose
uptake (Fig. 10). CM-PA treatment of skeletal muscle cells also
induces pro-inflammatory gene expression through the activation of
PKCh/e-NF-kB axis, which likely contributes further to the decline
in insulin action (Fig. 10). In the future, we aim to identify which of
the various inputs of PKC’s dominates in mediating the CM-PA-
induced insulin resistance in muscle cells. Overall, this study re-
establishes the participation of macrophages as a relay in the action
offattyacidsonmusclecells,and furtheridentifiesPKChand PKCe
as key elements in the inflammatory and insulinresistance responses
of muscle cells to macrophage products. Furthermore, it portrays
these PKC isoforms as a potential joint target for the treatment of
fatty acid-induced, inflammation-linked insulin resistance.
Supporting Information
Figure S1 Acute incubation of muscle cells with CM-PA
fails to activate novel PKC’s. Macrophages were treated with
BSA alone or 500 mM palmitate/1% BSA in culture medium for
6 h, then washed several times with PBS, and fresh medium was
added. After 12 h, conditioned media (CM-BSA, CM-PA) were
collected, centrifuged, and added to myoblast cultures for 1 h. As a
control, myoblasts were simultaneously incubated with exogenous
TNF-alpha (10 ng/ml for 1 h or 24 h). Lysates were prepared
from all conditions and equal amounts of protein from each
sample were immunoblotted with specific antibodies against
phospho-PKCh (Thr538) and phospho-PKCe (Ser729). Repre-
sentative gels of two experiments are shown.
(TIF)
Figure S2 Novel PKC inhibition does not prevent the
drop in insulin-stimulated tyrosine phosphorylation of
the insulin receptor observed with CM-PA. L6-GLUT4myc
cells expressing the human insulin receptor were treated for 24 h
with RM, CM-BSA and CM-PA. Where indicated, cells were pre-
incubated for 30 min with the novel and conventional PKC
inhibitor, Go ¨6983 (1 mM), prior to addition of CM-PA. Cells were
lysed and equal amount of total protein from each sample were
immunoblotted with anti-pY or anti-IR b-subunit either directly
or following stimulation with insulin (100 nM for 10 min).
Representative gels of two experiments are shown.
(TIF)
Figure S3 Short-term incubation of muscle cells with
CM-PA does not impact on insulin-stimulated phosphor-
ylation of Akt and AS160. Macrophages were treated with BSA
alone or 500 mM palmitate/1% BSA in culture medium for 6 h,
and then washed several times with PBS, and fresh medium was
added. After 12 h, conditioned media (CM-BSA, CM-PA) were
collected, centrifuged, and added to myoblast cultures for 1 h,
then myobalsts were serum-starved and pretreated with or without
insulin (100 nM, 20 min) as usual. As a control, myoblasts were
simultaneously incubated with exogenous TNF-alpha (10 ng/ml
for 1 h). Lysates were prepared and equal amount of protein from
each sample were immunoblotted with specific antibodies against
phospho-Akt (Ser473) and phospho-AS160. Representative gels of
two experiments are shown.
(TIF)
Figure S4 Individually silencing novel PKCh or e does
not restore insulin sensitivity in CM-PA treated myo-
blasts. L6-GLUT4myc myoblasts were treated for 24 h with RM,
CM-BSA, CM-PA, or CM-PA supplemented with siRNA to
PKCh or PKCe (100 nM each). Following 2 h of serum
starvation, myoblasts were stimulated in the presence or absence
of insulin (100 nM for 20 min). Cells were lysed, and equal
amount of total protein from each sample were immunoblotted
with specific antibodies against phospho-Akt (Ser473) and total
Akt (A), or phospho-AS160 and total AS-160 (B). Representative
immunoblots of two experiments are shown.
(TIF)
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